Emergence, Applications, And Challenges Of Biosimilars In The Indian Healthcare System


Anjali Bhardwaj, Seema Rohilla*

Geeta Institute of Pharmacy, Geeta University, Naultha-132145, Panipat, Haryana, India

E-mail: seemarohilla4@gmail.com

Abstract

This paper explores the realm of biosimilars and how they are transforming the pharmaceutical sector. Unlike generic pharmaceuticals, biosimilars are biologic therapies that are designed to closely mimic authorized reference biologics. This paper attempts to clarify the development and history of biologics, as well as the advantages and difficulties of biosimilars through a thorough examination. The biologic market is now more competitive because of the emergence of biosimilars, which have improved patient access to necessary therapies and reduced costs. Treatment flexibility provided by interchangeability may increase therapeutic adherence. With the production of several biosimilars, India's biopharmaceutical sector has become a powerful force. India's emphasis on biosimilars is in line with the worldwide trend toward affordable biological medicines, even if issues like standardizing legislation, ensuring quality, and encouraging innovation still exist.

Keywords: Biosimilar, Generic drug, Harmonizing regulations

1. Introduction: A Changing Pharma Identity

India has been one of the biggest suppliers by volume of generics during the last 20 years. Almost twenty percent of the world's generic medicine demand is supplied by Indian businesses, which are still growing. However, the global pharmaceutical sector is shifting toward more sophisticated, focused, and individualized treatments. At the vanguard of this change are biologics, which are sophisticated medications derived from living things. Biologics are the years to come of high-value, high-impact therapy alternatives, ranging from

vaccinations and monoclonal antibodies to cell and gene treatments. India's goal is now to become a worldwide leader in sophisticated biologics discovery, development, and production rather than just a low-cost manufacturing hub (1).

The treatment of several chronic and fatal illnesses, including various malignancies, autoimmune conditions, and metabolic abnormalities in the human body, has been transformed by biological products (2). However, the cost of original biologics is excessively costly, particularly in low- and medium-income countries (LMICs), which has restricted the accessibility to these treatments in nearly all circumstances (3). This need led to the creation of biosimilars. In terms of efficacy, purity, and potency, biosimilars are very identical to an already approved reference biologic; they do not exhibit clinically significant variations from the reference biologic in terms of immunogenicity or effectiveness (4). Because they are neither biologics nor comparable in terms of complexity, biosimilars are not considered generic goods. Furthermore, because they are derived from biological systems, they must be developed through rigorous, step-by-step demonstrations of comparability using conceptual, nonclinical, and clinical methods (5). Due to two considerations, the demand for biosimilars is expanding globally: the off-patent of popular biologics and the growing need for sustainable treatment choices and rising healthcare expenditures (6). Due to the Central Drugs Standard Control Organization's (CDSCO) significant involvement in establishing regulatory procedures, India has become a center for leading biosimilar development (7). This chapter gives a summary of the therapeutic uses of biosimilars in India for a range of illnesses, emphasizing both their clinical advantages and the difficulties in adopting and using them.

2. Background: The History and Development of Biologics

Biologics differ from traditional small-molecule medications in that they are large, complex molecules (typically proteins) made utilizing cutting-edge methods like cell culture systems and recombinant DNA technologies. Cancer, autoimmune illnesses, metabolic disorders, and other chronic and potentially fatal conditions can be treated using biologics. (8). Therefore, the advent of biopharmaceuticals throughout the last quarter of the 20th century marked a paradigm change in pharmacotherapy itself, which has highly targeted and precise modes of action. The creation of monoclonal antibodies and medicinal protein, which make up the majority of current biotherapeutic interventions, was made possible by some of the earlier instances, like recombinant insulin and erythropoietin (9).

2.1. Evolution of Biosimilars

Many prospects for biosimilars emerged when the patent durations for all popular biologics sold as therapeutic proteins or monoclonal antibodies ended (figure 1). It is clear that biosimilars are biologic medicines that have no clinically significant differences from a reference biologic in terms of quality, safety, and effectiveness. Because of the complex manufacturing methods and the variability in these biological systems, these biosimilars cannot be precisely replicated, unlike conventional pharmaceuticals (10). Biosimilars are not the same as the reference biologic, unlike generic medications. Due to the complexity of biologics and the manufacturing process, they exhibit slight differences in structure, post-translational modifications, and impurities compared to the reference biologic.

2.2. Approvals and Achievements:

The first biosimilar, Omnitrope® (somatropin), was approved by the European Medicines Agency (EMA) in 2006. Subsequent approvals were granted in highly regulated areas including the US and Japan (11). India was among the first to approve a biosimilar, a hepatitis B vaccination, in 2000. Since then, the worldwide pipeline has grown significantly, and several other biosimilars for endocrinology, rheumatology, and cancer are already available on the market (12). The function of patent expiration Numerous biosimilars has emerged as a result of the "patent cliff" for biologics including trastuzumab, rituximab, and adalimumab. Patent expiries have increased accessibility and lessened the financial strain on health care systems by opening up markets to less expensive alternatives (13).



Figure 1. Development phases and the timeline (in years) of reference biologics versus biosimilars.

3. Therapeutic Uses

Due to its robust pharmaceutical manufacturing capabilities, sizable patient population, and emphasis on expanding access to reasonably priced biologic medicines, India has become a major player in the global biosimilars industry. Many chronic and life-threatening illnesses that were previously solely treatable with expensive original biologics now have more treatment choices thanks to biosimilars.

3.1. Biosimilars in Different Domains

The development and growing use of biosimilars has had a major influence on India's therapeutic environment. Despite slight variations in therapeutically inert ingredients, these products have shown equivalent effectiveness, safety, and quality to an authorized reference biologic product. Their use covers a number of important disease domains and offers affordable substitutes for well-established biologic therapies.

3.1.1. Cancer

The National Comprehensive Cancer Network (NCCN) as well as American Society for Clinical Oncology (ASCO) recommend biologics for the treatment of various types of cancer because they improve clinical outcomes, notably overall survival (OS). Biologics are an important part of the modern cancer treatment arsenal. In the US health care system, biologics accounted for almost 55% of all antineoplastic medication spending, according to a 2011 drug spending analysis. Among these biologics are: (14).

- Nearly fifty percent of the top 20 antineoplastic expenses in outpatient clinics were attributed to trastuzumab (Herceptin; Roche). Human epidermal growth factor receptor 2 (HER2) positive breast cancer and metastatic gastric and gastroesophageal junction adenocarcinomas can be treated with **trastuzumab** (16).
- Colorectal, brain, lung, fallopian tube, kidney, and other malignancies can all be treated with **bevacizumab** (17).
- Leukemia and CD20-positive non-Hodgkin lymphoma can be treated with **rituximab** (18).

3.1.2. Rheumatology

The development of biologics has transformed rheumatology treatment and greatly enhanced patient outcomes. Rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile inflammatory arthritis are examples of systemic rheumatic illnesses with largely overlapping clinical symptoms of inflammation that are most damaging in and around

joints. The treatments employed for the illnesses also greatly overlap due to the parallels in key clinical characteristics. Methotrexate (MTX), leflunomide, sulfasalazine, and hydroxychloroquine were among the oral disease-modifying antirheumatic medications (DMARDs) that were typically used in earlier treatments. Since 1999, all of the new pharmaceuticals that have been presented have been biologics, which are proteins that have been produced in vitro and refined for subcutaneous or an injection through the IV Biosimilars improve patients' quality of life by providing a long-term solution for the management of chronic inflammatory illnesses (19).

- Antibodies or fusion proteins that inhibit the cytokine tumor necrosis factor alpha (TNFα) also known as anti-TNFα have made up the first class of biologics. As of right now, the United States has approved five such medications: golimumab (Simponi®), certolizumab pegol (Cimzia®), ADA (Humira®), etanercept (Enbrel®), and infliximab (Remicade®).
- Other biologics have targeted other elements of inflammatory pathways, such as B cells (rituximab), interleukin (IL)-1 (anakinra), the IL-6 receptor (tocilizumab), T-cell costimulation (abatacept) or T-cell costimulation and apoptosis (alefacept), and IL-12 and IL-23 (ustekinumab) (20).

3.1.3. Diabetes

Since the 1920s, insulin therapy has been a mainstay in the treatment of diabetes. It has developed from crude mammal extracts to highly pure human insulin produced by contemporary recombinant DNA technology. By enabling customized insulin regimes that replicate natural insulin secretion patterns, this development has greatly enhanced the quality and effectiveness of diabetes therapy. Patients now have access to a range of insulin formulations, such as combination, long-acting, and rapid-acting insulins, which are tailored to each patient's unique metabolic requirements and lifestyle (21). It is anticipated that the development of biosimilar insulins would increase competitiveness in the insulin market, which might reduce costs and improve access for patients who find original biologics too expensive. To guarantee their equivalency to reference products, biosimilars must undergo a thorough clinical examination because of the complicated regulatory environment and regional variations in standards (22).

4. Clinical Advantages of Biosimilars:

- **Treatment Flexibility:** Biosimilars enable smooth transitions between the reference biologic and the biosimilar without the need for intervention or notice to the prescribing physician. Healthcare professionals have additional treatment options thanks to this flexibility, which enables them to select the best therapy for their patients depending on their unique needs, reaction to treatment, and pharmaceutical availability (23).
- **Patient Preferences:** Certain dose forms or administration techniques (such as subcutaneous injection vs intravenous infusion) may be preferred by some patients. Biosimilars might provide different choices, meeting patient preferences and perhaps increasing adherence to therapy.
- **Cost Savings:** The ability of biosimilars to lower treatment costs is one of their most important advantages. Generally speaking, biosimilars are less expensive than the reference biologic, and interchangeability makes the substitution procedure easier, enabling medical professionals to prescribe the less expensive biosimilar without facing extra administrative challenges. Healthcare systems can reduce the cost of biologic medicines by including biosimilars in treatment plans. As a result, funds may be available for use in other facets of patient care along with medical research.
- **Patient Adherence:** Effective management of chronic illnesses depends on better treatment adherence. By enabling patients to regularly get their prescribed medicine even in the event of supply shortages or other problems with the reference biologic, interchangeable biosimilars can assure continuity of treatment. There is less chance of treatment disruptions brought on by things like shortages of goods or changes in insurance coverage when patients may easily transition between the reference biologic and its biosimilar. Better treatment results result from patients being able to continue the treatment without interruptions.
- **Enhanced Market Access and Competition:** The biologics market is more competitive as a result of the availability of biosimilars. Manufacturers may be encouraged to provide competitive prices when more biosimilars become interchangeable with the reference biologic, resulting in additional cost reductions for patients and healthcare systems. Patients' access to biologic treatments may be enhanced by interchangeable biosimilars. More patients can now afford these medicines, which could have been prohibitively expensive with the reference biologic alone, thanks to lower pricing and greater accessibility of biosimilars (24).

5. Role of India in Juggling Innovation and Affordability

As a leader in the pharmaceutical industry, India has a distinct story to tell. Despite being rated tenth in terms of value, its pharmaceutical market commands an excellent third place in terms of volume. These remarkable achievements highlight India's ability to develop innovative, reasonably priced vaccines and biosimilars, highlighting its position as a global competitor. Ultimately, the tale of biosimilars depicts change, creativity, and adaptability. It illustrates how economics, science, and legislation come together to produce a world where sophisticated biopharmaceuticals not only fight illnesses but also overcome obstacles to reach people who need them most (24).

BB (Biocon Biologics Limited), a pioneer with a history of successful approvals in the US, Europe, and other developed and developing countries, has had incredible successes in the field of biosimilars. Eight marketed goods from this prestigious firm have found their way into international markets. Being the first company to receive FDA clearance for an interchangeable biosimilar a feat accomplished with its Insulin Glargine is a significant milestone in its history. Over the course of the last 10 years, biosimilars have emerged as powerful substitutes for the expensive field of biologics (25).

They are strong competitors in the therapy of chronic illnesses, including cancer, diabetes, inflammation, and infections, receiving much-needed attention and creating new opportunities in the field of healthcare.

6. Barriers and Amendments

The inherent characteristics of biologic products provide difficulties. Replication and characterisation are challenging because of their complex and unstable composition, which contrasts with the stability of conventional medications. Even while switch studies have shown that interchangeable biosimilars are equivalent, they might not always be better than other biosimilars. The preference for adaptable biosimilars versus generic biosimilars may be confused by this differential (26).

Even when more reasonably priced biosimilars are available, patient and physician preferences frequently favor certain insulins or delivery methods, leading to resistance to treatment adjustments. Patients and healthcare professionals may get overwhelmed by the abundance of options as the market grows with additional authorized biosimilar insulins. This emphasizes the necessity of thorough education in order to enable a smooth transition. A key factor in the broader use of biosimilar insulins will be educating patients and healthcare professionals about the transition from reference insulin to biosimilar insulin variations.

7. Strengths and Positive Contributing Factors:

Young and ambitious workforce: The existence of a young and driven staff can support industry innovation, research, and development.

Cost competitiveness: The capacity to manufacture vaccines and biosimilars at a lower cost than in other areas can boost competitiveness and possibly result in greater market shares. **High efficacy, low cost, and equivalent safety level:** The healthcare business may be drawn to the industry's emphasis on creating high-quality biosimilars for lower costs with comparable safety levels to original goods (27).

Low-cost, inexpensive biosimilars: In the price-conscious Indian market, inexpensive biosimilars can make drugs more affordable, increasing market penetration and acceptance.

Reduced cycle in synthesis along with regulatory compliance: Biosimilars can be developed and introduced to the market more quickly if they are synthesized and comply with regulations more quickly than innovator molecules.

Government regulatory support: Government regulatory help can guarantee adherence to quality standards and expedite the production of biosimilars.

Government activities: The industry's growth and development can be accelerated by government programs that promote investment and foster trust (28).

8. Conclusion

The development of biosimilars is a testament to the complex interactions between science, policy, and economics in pharmaceutical innovation and regulation. Unlike conventional small-molecule medications, biosimilars have carved out an own route by navigating the challenging seas of clinical equivalency as a break from patent dependency. India plays a significant role in this story, becoming a major player in the global biopharmaceutical market. India has established itself as a global leader in the supply of generic drugs and the demand for vaccines thanks to a mix of innovative firms like Biocon and Dr. Reddy's and more recent entrants like Enzyme Biosciences Ltd. The difficulties in promoting innovation, enhancing quality control, and harmonizing laws highlight how India's biopharma sector is still developing.

Biosimilars provide a powerful option as the world's healthcare system struggles with illnesses and financial obstacles. This revolutionary path, characterized by achievements, difficulties, and continuous innovation, demonstrates the pharmaceutical industry's extraordinary resilience in meeting the constantly changing requirements of patients throughout the globe. Enhanced regulatory frameworks, better education, and a broader use of biosimilars to provide easily accessible, reasonably priced, and efficient healthcare solutions to people who most need them are all promising aspects of the future.

9. References

1. Calleja MA, Albanell J, Aranda E, García-Foncillas J, Feliu A, Rivera F, et al. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. European Journal of Hospital Pharmacy. 2023;30(e1): e40. DOI: 10.1136/ejhpharm-2021-002955
2. Wolff-Holz E., Tiitso K., Vleminckx C., Weise M. Evolution of the EU Biosimilar Framework: Past and Future. BioDrugs. 2019; 33:621–634. doi: 10.1007/s40259-019-00377-y.
3. Afzali A., Furtner D., Melsheimer R., Molloy P.J. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Adv. Ther. 2021; 38:2077–2093. doi: 10.1007/s12325-021-01688-9.
4. Isaacs J., Gonçalves J., Strohal R., Castañeda-Hernández G., Azevedo V., Dörner T., McInnes I. The biosimilar approval process: How different is it. Consid. Med. 2017; 1:3–6. doi: 10.1136/conmed-2017-100003.
5. Blandizzi C., Meroni P.L., Lapadula G. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clin. Ther.2017;39:1026–1039. doi: 10.1016/j.clinthera.2017.03.014.
6. Mirjalili S.Z., Sabourian R., Sadeghalvad M., Rezaei N. Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders. Int. Immunopharmacol. 2021; 101:108305. doi: 10.1016/j.intimp.2021.108305.
7. Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing: Current perspectives. BioDrugs. 2021; 35:1–14. doi:10.1007/s40259-020-00458-2.
8. Halimi V., Daci A., Ancevska Net kovska K., Suturkova L., Babar Z.U., Grozdanova A. Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. Int. J. Environ. Res. Public Health. 2020; 17:5800. doi: 10.3390/ijerph17165800.
9. Declerck P., Danesi R., Petersel D., Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017; 77:671–677. doi: 10.1007/s40265-017-0717-1.
10. Mitra S., Murthy G.S. Bioreactor control systems in the biopharmaceutical industry: A critical perspective. Syst. Microbiol. Biomanuf. 2022; 2:91–112. doi: 10.1007/s43393-021-00048-6.
11. Declerck P., Farouk Rezk M. The road from development to approval: Evaluating the body of evidence to confirm biosimilarity. Rheumatology. 2017; 56: iv4–iv13. doi: 10.1093/rheumatology/kex279.
12. Meher BR, Balan S, Mohanty RR, Jena M, Das S. Biosimilars in India; Current Status and Future Perspectives. J Pharm Bioallied Sci. 2019 Jan-Mar;11(1):12-15. doi: 10.4103/jpbs.JPBS_167_18. PMID: 30906134; PMCID: PMC6394151.
13. Ismail S., Abu Esba L.,Khan M., Al-Abdulkari H., Modimagh H., Yousef C. An Institutional Guide for Formulary Decisions of Biosimilars. Hosp. Pharm. 2023; 58:38–48. doi: 10.1177/00185787221138007.
14. Abraham J. Developing oncology biosimilars: An essential approach for the future. Semin Oncol. 2013;40(suppl 1): S5–S24. doi: 10.1053/j.seminoncol.2013.09.015.
15. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: Regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9(suppl 4): S1–S22. doi: 10.6004/jnccn.2011.0136.
16. Hanna NH, Schneider BJ, Temin S, et al. Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (Ontario Health) guideline update. J Clin Oncol. 2021;39(9):1040–1091**.** doi:10.1200/JCO.20.03570.
17. Patterson JA, et al. Medicare Part D coverage of drugs selected for the drug price negotiation program. JAMA Health Forum. 2024;5(2): e240123. doi:10.1001/jamahealthforum.2024.0123.
18. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22:7359–7368. Doi. 10.1038/sj.onc.1206939.
19. Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468. doi: 10.1001/jama.2011.406.
20. Heinemann L, Davies M, Home P, Forst T, Vilsbøll T, Schnell O. Understanding biosimilar insulins - development, manufacturing, and clinical trials. J Diabetes Sci Technol 2023; 17:1649-61. DOI: 10.1177/19322968221105864
21. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations--a cause for concern? Diabetes Technol Ther 2012; 14:989-96. DOI: 10.1089/dia.2012.0105
22. Patel A, Bhatt N, Prakash SS, Biswas G, Nagarkar R, Roy B, Samal P, Agrawal N, Meshram S, Kaushal A, Satheesh CT. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India. Cancer Chemotherapy and Pharmacology. 2023 Jun;91(6):457-68. DOI: 10.1007/s00280-023-04530-x
23. Bashir NS, Hughes A, Ungar WJ. Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. MDM Policy & Practice. 2023 Feb;8(1):23814683231156433. DOI: 10.1177/23814683231156433
24. Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Frontiers in Pharmacology. 2023 Apr 21;14: 1151764. doi: 10.3389/fphar.2023.1151764.
25. Zeng X, Jia Y, Chen H, Luo Q, Zhao H, Liang G, Chen W, Li Y. A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 2023 May 16:1-7. DOI: 10.1007/s00432-023-04775-2

26. Patel A, Bhatt N, Prakash SS, Biswas G, Nagarkar R, Roy B, Samal P, Agrawal N, Meshram S, Kaushal A, Satheesh CT. Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India. Cancer Chemotherapy and Pharmacology. 2023 Jun;91(6):457-68. DOI: 10.1007/s00280-023-04530
27. Bashir NS, Hughes A, Ungar WJ. Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. MDM Policy & Practice. 2023 Feb;8(1):23814683231156433. DOI: 10.1177/23814683231156433
28. Yu T, Jin S, Li C, Chambers JD, Hlávka JP. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans. BioDrugs. 2023 Apr 1:1-0. DOI: 10.1007/s40259-023-00593-7